A human clinical study found that supplementation with a blend of Chinese Chastetree (Vitex negundo) and ginger (Zingiber officinale) marketed as Muvz by OmniActive Health Technologies was associated with self-reported improvements in joint and lower back comfort. The findings were published in Drug Design, Development, and Therapy.

The three month double-blind study involved 157 adults between the ages of 40 and 60, who were administered Muvz at a single 200 mg dose or a 200 mg dose twice per day.

Supplementation with Muvz at both doses was associated with significant improvements in scores on questionnaires measuring musculoskeletal health indicators by day 30. By day 90, both treatment groups reported significantly improved measures of joint and low back comfort, and reduced discomfort after physical activity. They also, on average, experienced improvements in active and passive flexion range of motion by day 90.

“We are excited to see this new publication validating the benefits of Muvz in supporting joint and low-back comfort with improved mobility, particularly for those with knee and lower back discomfort,” said Abhijeet Morde, senior director of in vitro biology, animal studies, and clinical research at OmniActive. “The results align with previous studies, further reinforcing Muvz as a natural, ingredient solution for supporting mobility through joint and low-back comfort support as well as flexibility in physically active individuals.”

“The global joint health market sits at over $11.5 billion, which is being propelled by younger, active consumers and athletes,” said Keya Shah, assistant director of OmniActive’s joint health category. “Muvz continued to demonstrate significant benefits for mobility and with this new research, we’re well-positioned to meet the growing demand for high-quality plant-based ingredients that may help support consumers of various activity levels who are looking for better mobility and improved quality of life.”